Search results
Results from the WOW.Com Content Network
The Framingham Risk Score is a sex-specific algorithm used to estimate the 10-year cardiovascular risk of an individual. The Framingham Risk Score was first developed based on data obtained from the Framingham Heart Study, to estimate the 10-year risk of developing coronary heart disease. [1]
QRISK3 (the most recent version of QRISK) is a prediction algorithm for cardiovascular disease (CVD) that uses traditional risk factors (age, systolic blood pressure, smoking status and ratio of total serum cholesterol to high-density lipoprotein cholesterol) together with body mass index, ethnicity, measures of deprivation, family history, chronic kidney disease, rheumatoid arthritis, atrial ...
These guidelines recommend statin therapy for adults between forty and seventy-five who have diabetes, high cholesterol levels, or an estimated 10-year atherosclerotic cardiovascular disease risk ...
They recommended selective use of low-to-moderate doses statins in the same adults who have a calculated 10-year cardiovascular disease event risk of 7.5–10% or greater. [23] In people over the age of 70, statins decrease the risk of cardiovascular disease but only in those with a history of heavy cholesterol blockage in their arteries. [25]
For people ages 40 to 60, 35–40% died of heart-related disease. To find out whether statin use could help lower death risk from heart disease among older adults in these age groups, the authors ...
Elevated blood pressure can progress to heart failure. Framingham Risk Score is published, and correctly predicts 10-year risk of future coronary heart disease (CHD) events. At 40 years of age, the lifetime risk for CHD is 50% for men and 33% for women. 2000s
A United States guideline recommends statins in those who have a 12% or greater risk of cardiovascular disease over the next ten years. [166] Niacin, fibrates and CETP Inhibitors, while they may increase HDL cholesterol do not affect the risk of cardiovascular disease in those who are already on statins. [167]
This increases the risk of, or aggravate, atherosclerotic cardiovascular disease (ASCVD). Therefore, antihyperlipidemic drugs are introduced for primary and secondary coronary heart disease prevention, as well as for reduction in mortality from acute coronary outcomes. [18] These drugs include statins, ezetimibe and fibrates.